-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Zejing Pharmaceutical Donafinil Tosylate Tablets (hereinafter referred to as "donafinil") in the treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer (RAIR-DTC) is a multi-center, random, double The blinded, placebo-controlled Phase III clinical trial (code: ZGDD3) carried out a predetermined interim analysis, and the Independent Data Monitoring Committee (IDMC) reviewed the results and determined that the effectiveness and safety results were in line with expectations
The ZGDD3 Phase III clinical trial terminates the trial early after reaching the endpoint of the interim analysis, which will accelerate the marketing process of Donafenib's local advanced/metastatic radioiodine refractory differentiated thyroid cancer indications
About clinical trials (ZGDD3)
In 2019, the National Cancer Center estimated that the incidence of thyroid cancer in China reached 201,000, with an incidence rate of 14.
"A multi-center, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effectiveness and safety of Donafenib tosylate tablets in the treatment of locally advanced/metastatic RAIR-DTC" (Code: ZGDD3), co-planned 204 patients were enrolled, and the main purpose was to evaluate the progression-free survival (PFS) of Donafenib tosylate tablets in the treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer (RAIR-DTC)
About Donafinil Tosylate Tablets
Donafinil is an oral multi-target, multi-kinase inhibitor class of small molecule anti-tumor drugs.
Donafenib has been included in the "CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer 2020", "Chinese Expert Consensus on Perioperative Management of Liver Cancer and Liver Resection (2021 Edition)", "Expert Consensus on Targeted Therapy of Liver Cancer (Draft)-2020", " Chinese Expert Consensus on Multidisciplinary Comprehensive Treatment of Liver Cancer, “Chinese Guidelines for Radiotherapy of Primary Hepatocellular Carcinoma (2020 Edition)”, “Chinese Clinical Practice Guidelines for Transarterial Chemoembolization (TACE) Therapy of Liver Cancer (2021 Edition)”
